Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Tolerability of Mirabegron Compared to Oxybutynin Chloride Immediate Release for Neurogenic Detrusor Overactivity in Persons With Chronic Spinal Cord Injury: A Randomized, Double-Blind, Controlled, Cross-Over Clinical Trial

Trial Profile

Efficacy and Tolerability of Mirabegron Compared to Oxybutynin Chloride Immediate Release for Neurogenic Detrusor Overactivity in Persons With Chronic Spinal Cord Injury: A Randomized, Double-Blind, Controlled, Cross-Over Clinical Trial

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs Mirabegron (Primary) ; Oxybutynin (Primary)
  • Indications Detrusor instability; Overactive bladder
  • Focus Therapeutic Use
  • Acronyms MOSET-SCI
  • Most Recent Events

    • 08 Aug 2018 Planned initiation date changed from 8 Jan 2018 to 1 Sep 2018.
    • 29 Nov 2017 Planned initiation date changed from 15 Sep 2017 to 8 Jan 2018.
    • 16 Aug 2017 Planned initiation date changed from 5 Jul 2017 to 15 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top